Soleno Therapeutics (SLNO) Stock Price, Quote, News & History

Comments

Soleno Therapeutics Inc (SLNO) Stock Price, Quote, News & History

SLNONASDAQ

Trade with Public

$39.07

0.982.57%

At close: Feb 27, 4:00 PM EST

$41.70

2.636.73%

After Hours: Feb 27, 7:45 PM EST

Earnings: Q4 2025 Earnings were released on Wed Feb 25th, after the market close

Conference Call: The most recent conference call started at 4:30 PM, 4 days ago

Click to view the webcast

OverviewNews Earnings Options Guidance Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

$37.85

Close

$39.07

Volume / Avg.

1.54M / 1.52M

Day Range

$37.85 - $39.07

52 Wk Range

32.63 - 90.32

Market Cap

$2.24B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

55

Short Interest

20.6%

Days to Cover

6.61

Recent Soleno Therapeutics Inc News

Rhythm Pharmaceuticals Is Well-Positioned, Analyst Says Could Capture Big Share Of Rare Obesity Market

RBC launches Rhythm Pharma with Outperform, sees $2 billion Imcivree sales by 2030 after Phase 3 obesity data boost.

Vandana Singh

Peakstone Realty Trust, Aquestive Therapeutics, Opera And Other Big Stocks Moving Higher On Monday

Avi Kapoor

Rhythm Pharma Strikes Chord As Early PWS Trial Results Show Promise

Rhythm Pharma rises after early Prader-Willi trial data show reduced hunger and BMI, supporting plans for a Phase 3 study of setmelanotide.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-25.90M

Investing Cash Flow (TTM)

-69.98M

Financing Cash Flow (TTM)

294.12M

Free Cash Flow (TTM)

-25.92M

Capital Expenditure (TTM)

-23.00K

Net Change in Cash (TTM)

198.25M

Analyst Trends and Forecast

2

Nov 25

2

Jan

2

Feb

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.65B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

18.71

PB Ratio (TTM)

4.13

Earnings Yield % (TTM)

-4.60%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$9.21

Company Debt

Total Debt

$49.85M

LT Debt

$49.85M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$246.66M

Debt to Equity

0.11

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$37.85

Close

$39.07

Volume / Avg.

1.54M / 1.52M

Day Range

$37.85 - $39.07

52 Wk Range

32.63 - 90.32

Market Cap

$2.24B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

55

Short Interest

20.6%

Days to Cover

6.61

About

Sector

Health Care

Industry

Biotechnology

Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a cryst...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Soleno Therapeutics (SLNO) stock?

A

You can purchase shares of Soleno Therapeutics (NASDAQ:SLNO) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Soleno Therapeutics (SLNO) competitors?

A

Other companies in Soleno Therapeutics’s space includes: Galecto Inc (NASDAQ:GLTO), Immunome Inc (NASDAQ:IMNM), Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), Sarepta Therapeutics Inc (NASDAQ:SRPT) and Ascentage Pharma Group International (NASDAQ:AAPG).

Q

What is the forecast, or price target, for Soleno Therapeutics (SLNO) stock?

A

Soleno Therapeutics has a consensus price target of $106.83.

Q

What is the current price for Soleno Therapeutics (SLNO)?

A

The stock price for Soleno Therapeutics (NASDAQ: SLNO) is $41.7 last updated February 27, 2026 at 7:45 PM EST.

Q

Does Soleno Therapeutics (SLNO) pay a dividend?

A

There are no upcoming dividends for Soleno Therapeutics.

Q

When is Soleno Therapeutics (NASDAQ:SLNO) reporting earnings?

A

Soleno Therapeutics does not have any upcoming earnings scheduled.

Q

Is Soleno Therapeutics (SLNO) going to split?

A

There is no upcoming split for Soleno Therapeutics.

Q

What sector and industry does Soleno Therapeutics (SLNO) operate in?

A

Soleno Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Ultragenyx Pharmaceutical Inc

NASDAQ:RARE

$23.39

%

Sarepta Therapeutics Inc

NASDAQ:SRPT

$16.62

-0.84%

AAPG

Syndax Pharmaceuticals Inc

Key Statistics

Open

$37.85

Close

$39.07

Volume / Avg.

1.54M / 1.52M

Day Range

$37.85 - $39.07

52 Wk Range

32.63 - 90.32

Market Cap

$2.24B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

55

Short Interest

20.6%

Days to Cover

6.61

Recent Soleno Therapeutics Inc News

Rhythm Pharmaceuticals Is Well-Positioned, Analyst Says Could Capture Big Share Of Rare Obesity Market

RBC launches Rhythm Pharma with Outperform, sees $2 billion Imcivree sales by 2030 after Phase 3 obesity data boost.

Vandana Singh

Peakstone Realty Trust, Aquestive Therapeutics, Opera And Other Big Stocks Moving Higher On Monday

Avi Kapoor

Rhythm Pharma Strikes Chord As Early PWS Trial Results Show Promise

Rhythm Pharma rises after early Prader-Willi trial data show reduced hunger and BMI, supporting plans for a Phase 3 study of setmelanotide.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-25.90M

Investing Cash Flow (TTM)

-69.98M

Financing Cash Flow (TTM)

294.12M

Free Cash Flow (TTM)

-25.92M

Capital Expenditure (TTM)

-23.00K

Net Change in Cash (TTM)

198.25M

Analyst Trends and Forecast

2

Nov 25

2

Jan

2

Feb

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.65B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

18.71

PB Ratio (TTM)

4.13

Earnings Yield % (TTM)

-4.60%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$9.21

Company Debt

Total Debt

$49.85M

LT Debt

$49.85M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$246.66M

Debt to Equity

0.11

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$37.85

Close

$39.07

Volume / Avg.

1.54M / 1.52M

Day Range

$37.85 - $39.07

52 Wk Range

32.63 - 90.32

Market Cap

$2.24B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

55

Short Interest

20.6%

Days to Cover

6.61

About

Sector

Health Care

Industry

Biotechnology

Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a cryst...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry